Evidence map›Paper›PMID 40230732›Full record

ArticleCureus2025

Severe Epistaxis Due to Risankizumab: A Case Report.

Judith P Vinod, Nicholas Gallo, Julio Gonzalez, Christopher Delange, Alejandro Biglione

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far?Journal of inflammation research · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Judith P VinodInternal Medicine, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, USA.
Nicholas GalloInternal Medicine, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, USA.
Julio GonzalezInternal Medicine, Wellington Regional Medical Center, Wellington, USA.
Christopher DelangeInternal Medicine, Wellington Regional Medical Center, Wellington, USA.
Alejandro BiglioneInternal Medicine, Wellington Regional Medical Center, Wellington, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Risankizumab is a novel treatment for plaque psoriasis, approved for treatment in the US in 2019. It is a humanized monoclonal antibody that demonstrates high efficacy and safety, both in short-term and long-term usage. Like many modern medications, risankizumab has some reported adverse effects. The most common of these reported adverse effects, affecting more than 20% of users, is nasopharyngitis. This case report discusses a 76-year-old female patient who presented to the emergency department for severe epistaxis while receiving risankizumab as treatment for plaque psoriasis.

Indexed as

il-23 inhibitorsimmunotherapy-related adverse eventsmanagement of severe epistaxisrisankizumabs: epistaxissevere epistaxis

Identifiers

PMID40230732
PMCPMC11996231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.